GENE ONLINE|News &
Opinion
Blog

2022-03-01| R&D

Transcriptional Programs Uncovering the Genetic Causes of Psychiatric Disorders

by Manju Bhaskar
Share To

Brain development is a complex choreography of cell proliferation, specification, growth, migration and network formation. Distinct genes are expressed during early excitatory corticoneurogenesis in vitro and in the human fetal cortex. Coordinated programs of gene expression drive brain development. Variants of these genetic expression platforms contribute to a wide spectrum of disorders and cognitive function. 

Related Article: Big Pharma and Non-Profits Join NIH, FDA in New Rare Diseases Drive

Schizophrenia Genes

 

Schizophrenia (SZ) is a highly heritable, psychiatric disorder, with genetic variations ranging from common polymorphisms (SNPs) to rare mutations contributing to disease risk. Genome wide association studies (GWAS) was able to identify SZ gene sets in a modest proportion of a common variant association signal. 50% of genetic SNP-based heritability is captured by loss-of-function intolerant (LoFi) genes. Rare variation in LoFi genes, including many of those implicated in other psychiatric disorders, also contributes to SZ. DLG2, also known as postsynaptic density protein-in (PSD-93) or chapsyn-110, plays a critical role in the molecular organization of multi-protein complexes at the excitatory synapse. In the mature neurons DLG2 is required for normal formation of NMDA receptor signaling complexes. It is abundantly expressed throughout rodent adult brain, including the cortex, hippocampus, striatum, and cerebellum. 

Sanders et al., from Cardiff University, University of Sheffield and other premiere institutes in the UK explored the role of DLG2 in neurodevelopment using hESCs (human embryonic stem cells) with DLG-/- loss of function mutation using the CRSIPR-CAS9 system. The team of scientists also investigated the relationship between developmental and mature neuronal pathways in SZ.

Based on the research findings, the team of scientists propose that each variant gene set form a transcriptional cascade regulating neuronal growth, migration, differentiation and network formation. Computational analyses of gene/mRNA regulatory interactions implicate known neurodevelopmental disorder risk genes (CHD8, TCF4, FMRP, BCL11B and TBR1) as regulators of this cascade and reveal pathways through which they may contribute to the disease. A noteworthy observation was down-regulation of neurogenic programs in DLG-/- lines leads to impaired migration, immature action potential generation and delayed expression of cell-type identity of other relevant proteins. It was further confirmed that genetic risk for all disorders was concentrated in LoFi genes, indicating wider relevance for these genes in psychiatric disorders. The study revealed that DLG2 expression is important for cortical excitatory neurodevelopment, but the mechanism by which it operates remains to be determined. Based on its function and the involvement of invertebrate DLG in the developmental Scrib signaling module, DLG may link cell-surface receptors to signal transduction pathways regulating the activation of neurogenic programs. 

Although much remains to be uncovered, the study findings sketch the foundations for an integrated etiological model of psychiatric genetic disorders and their developmental origins. 

Related Article: FDA Approves Drug for Schizophrenia in Pediatric Patients

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
R&D
Inside the Aging Brain: NTU Singapore’s Revelation on Memory Neuron Communication
2024-01-24
GeneOnline’s Weekly News Highlights: Aug 21-25
2023-08-28
A New Phase in Drug Development: Programming the Genome
2023-03-02
LATEST
Lotus Pharma Expands in Southeast Asia with Alpha Choay Acquisition from Sanofi
2024-09-06
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void
2024-09-05
Breaking New Ground for Clinical Trials with AI/ML Applications
2024-09-05
InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment
2024-09-04
Alnylam Pharma Shares Dip Despite Positive Phase 3 HELIOS-B Heart Disease Results
2024-09-04
EVENT
2024-09-11
2024 Bio Asia Pacific
Bangkok, Thailand
2024-09-13
ESMO Congress 2024
Barcelona, Spain
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
Scroll to Top